Xeris Biopharma Holdings, Inc.
DE ˙ DB ˙ US98422E1038
4,98 € ↓ -0,09 (-1,79%)
2026-06-04
DEL PRIS
SecurityDE:2B30 / Xeris Biopharma Holdings, Inc.
InstitutionPrudential Financial Inc
Latest Disclosed Ownership57,139 shares
Latest Disclosed Value $ 331,406
Prudential Financial Inc reports 90.77% decrease in ownership of 2B30 / Xeris Biopharma Holdings, Inc.

On May 13, 2026 - Prudential Financial Inc filed a 13F-HR form disclosing ownership of 57,139 shares of Xeris Biopharma Holdings, Inc. (DE:2B30) valued at $275,524 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 618,949 shares of Xeris Biopharma Holdings, Inc.. This represents a change in shares of -90.77% during the quarter. The current value of the position is $284,609 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 57,139 -561,810 -90.77 331 -93.19 0.0002
2026-02-13 2025-12-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 618,949 -815,255 -56.84 4,859 -58.39 0.0059
2025-11-13 2025-09-30 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 1,434,204 -122,425 -7.86 11,674 60.60 0.0139
2025-08-12 2025-06-30 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 1,556,629 457,784 41.66 7,269 20.51 0.0094
2025-05-13 2025-03-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 1,098,845 1,061,900 2,874.27 6,033 4,725.60 0.0086
2025-02-11 2024-12-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 36,945 7,000 23.38 125 47.06 0.0002
2024-11-14 2024-09-30 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 29,945 29,945 85 0.0001
2024-08-13 2024-06-30 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 0 -28,675 -100.00 0 -100.00
2024-05-14 2024-03-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 28,675 -2,800 -8.90 63 -13.70 0.0001
2024-02-13 2023-12-31 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 31,475 0 0.00 74 25.86 0.0001
2023-11-13 2023-09-30 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 31,475 -127,400 -80.19 59 -86.06 0.0001
2023-08-11 2023-06-30 13F XERIS BIOPHARMA HOLDINGS COM 98422E103 158,875 158,875 416 0.0006
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.